Efficacy of Levonorgestrel-releasing Intrauterine System Versus Oral Progestins in Treatment of Simple Endometrial Hyperplasia Without Atypia
Overview
Affiliations
Objective: To evaluate the efficacy of 3 progestin treatment regimens in the management of simple endometrial hyperplasia without cytological atypia in premenopausal women.
Study Design: Prospective randomized comparative study. The study included 90 premenopausal women with histological diagnosis of simple endometrial hyperplasia (EH) without atypia, during the period from January 2010 to March 2012, at TAIBA Hospital in Kuwait. Patients were randomly allocated to 3 groups of 30 patients each receiving medroxyprogesterone acetate (MPA, 10 mg/d; group I), norethisterone (NET, 15 mg/d; group II) for 10 days per cycle, or insertion of levonorgestrel-releasing intrauterine system (LNG-IUS; group III). Patients were reevaluated after 3 months of treatment. Patients with regression and persistence were offered the same medication they were using for another 3 months. The primary outcome of the study was the proportion of patients requiring further treatment for another 3 months.
Results: Patients in the LNG-IUS group showed the highest resolution rate (66.67%). Patients in MPA group had a resolution rate of 36.66% where the resolution rate was 40% in patients of NET group. The patients having LNG-IUS showed a regression rate of 33.3%, whereas patients receiving MPA and NET showed a regression rate of 60% and 56.67%, respectively. There was a statistically significant difference between the 3 groups regarding the proportion of patients requiring further treatment for another 3 months (χ(2) = 6.501; P = .0387).
Conclusion: The LNG-IUS appears to represent an effective superior convenient treatment option for simple EH without atypia.
Tao M, Wu T, Zhou X, Du X, Ling K, Liang Z Arch Gynecol Obstet. 2024; 310(3):1315-1329.
PMID: 38980346 DOI: 10.1007/s00404-024-07608-w.
Zhang Y, Fan Y, Mu Y, Li J J Clin Med. 2023; 12(8).
PMID: 37109316 PMC: 10143726. DOI: 10.3390/jcm12082980.
Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia.
Girbash E, Sherif H, Radwan A, Abdeldayem H Arch Gynecol Obstet. 2023; 308(3):947-952.
PMID: 37010614 PMC: 10348941. DOI: 10.1007/s00404-023-07015-7.
Endometrial hyperplasia as a risk factor of endometrial cancer.
Nees L, Heublein S, Steinmacher S, Juhasz-Boss I, Brucker S, Tempfer C Arch Gynecol Obstet. 2022; 306(2):407-421.
PMID: 35001185 PMC: 9349105. DOI: 10.1007/s00404-021-06380-5.
Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T, Farrant C, Wise M Cochrane Database Syst Rev. 2020; 9:CD012658.
PMID: 32909630 PMC: 8200645. DOI: 10.1002/14651858.CD012658.pub2.